ACOG:CC - Alpha Cognition to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday April 26 2023 & 1x1 Meetings on Thursday April 27 2023

VANCOUVER, BC / ACCESSWIRE / April 5, 2023 / Alpha Cognition Inc. (TSX-V:ACOG)(OTCQB:ACOGF), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 10:30AM (Local Time -PST). Michael McFadden, CEO of Alpha Cognition, will be hosting the presentation and answering questions at the conclusion.

To access the live presentation, please use the following information:

Planet MicroCap Showcase: VEGAS 2023
Date: Wednesday, April 26th, 2023
Time: 1:30 PM Eastern Time (10:30 AM Pacific Time)
Webcast: https://www.webcaster4.com/Webcast/Page/2963/47987

If you would like to book 1x1 investor meetings with Alpha Cognition, and to attend the Planet MicroCap Showcase: VEGAS 2023, please make sure you are registered here: https://planetmicrocapshowcase.com/signup

1x1 meetings will be scheduled and conducted in person at the conference venue in LAS VEGAS.

The Planet MicroCap Showcase: VEGAS 2023 website is available here:
https://planetmicrocapshowcase.com/

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://planetmicrocapshowcase.com/agenda

News Compliments of Accesswire

About Alpha Cognition

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS), for which there are limited treatment options.

ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury.

About Planet MicroCap

Planet MicroCap is a global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space.

If you would like to attend the Planet MicroCap Showcase, please register here: https://planetmicrocapshowcase.com/signup

Contact:
info@alphacognition.com
https://www.alphacognition.com/

SOURCE: Alpha Cognitionvia SNN Network